IDH2 and glioblastoma: Table 1 shows the clinical information from TCGA (LGG-GBM) of 670 patients with glioma, whose data were used in this study, including age, gender, race, primary therapy outcome, WHO grade, histological type, IDH status, 1p/19q codeletion, epidermal growth factor receptor (EGFR) status and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) status.